Ronapreve™ (casirivimab and imdevimab, known as REGEN-COV™ in the United States) is approved for the treatment of patients with COVID-19 in the European Union, Japan, New Zealand and Switzerland, conditionally approved in Australia and the United Kingdom, and authorised for emergency or temporary pandemic use in additional territories such as Canada and the US. It has also been conditionally recommended by the World Health Organization (WHO) for the treatment of patients with COVID-19.
Ronapreve is available to COVID-19 patients in more than 50 countries, including upper-middle- and lower-middle-income countries. The efficacy and safety of Ronapreve have been studied across multiple phase III clinical trials in non-hospitalised and hospitalised COVID-19 patients, and in the preventive setting.
Ronapreve is being jointly developed by Roche and Regeneron. It is a combination of two monoclonal antibodies, casirivimab and imdevimab, and was designed to block infectivity of SARS-CoV-2, the virus that causes COVID-19. Recent in vitro analyses and structural modelling have shown that Ronapreve has diminished potency versus the SARS-CoV-2 variant of concern, Omicron (B.1.1.529) while it has shown to retain its activity against all other main variants of concern, including Delta (B.1.617.2).